Genetic Microdevices Ltd

genetic-microdevices.co.uk

Genetic Microdevices Ltd has developed a disruptive technology that analyses proteins and DNA with ultra-high performance. The instrument is based on a disposable analysis chip. Protein and DNA analysis are central to any biological analysis including drug development, research and diagnostics. Our device encompasses unique intellectual property which makes it far more potent than directly competing analytical devices. A key feature of the technology is that it performs the advanced analysis using a disposable microfluidic cartridge that can separate biological molecules with unprecedented sensitivity and resolution.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industry Outlook

IONPATH EXPANDS PARTNERSHIPS FOR RAPIDLY DELIVER NOVEL INSIGHTS UTILIZING COMPANY'S HIGH-DEFINITION SPATIAL PROTEOMICS PLATFORM

IONpath, Inc. | August 27, 2021

news image

Ionpath, Inc., the leader in high-definition spatial proteomics, today announced a new program for biopharmaceutical research organizations interested in piloting spatial phenotyping analyses of tissue samples leveraging the company's Multiplexed Ion Beam Imaging (MIBI™) technology. Through this new program, customers can benefit from in-depth immune profiling and spatial analysis performed with the company's 30-marker Checkpoint Panel on its MIBIscope™ System. ...

Read More

OBSIDIAN THERAPEUTICS ANNOUNCES BRISTOL MYERS SQUIBB OPT-IN OF CYTODRIVE™ CELL THERAPY CANDIDATE

Obsidian Therapeutics | September 16, 2020

news image

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first opt-in decision by Bristol Myers Squibb since the companies announced their collaboration to develop nov...

Read More

Cell and Gene Therapy

EXACT SCIENCES ACQUIRES PREVENTIONGENETICS TO ACCELERATE AVAILABILITY OF HEREDITARY CANCER TESTING FOR MORE PATIENTS

Exact Sciences Corporation | January 10, 2022

news image

Exact Sciences Corp. announced it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT). PreventionGenetics provides the clinical lab, expertise, and foundational technology necessary to accelerate the availability of HCT and help more patients know their germline risk of cancer and other diseases. "PreventionGenetics is a natura...

Read More

Cell and Gene Therapy

CURI BIO CLOSES $10M SERIES A IN OVERSUBSCRIBED ROUND

Curi Bio Inc. | December 30, 2021

news image

Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced the second closing of a $10 million oversubscribed Series A financing. New investors include UTC Investment and DS Asset Management, joining current Curi Bio investor and Series A lead Dynamk Capital. The investment will be used to scale Curi’s existing business and accelerate the development of its innovative engineered tissue analysis platforms, including its Mantarray™ platform.
Read More

news image

Industry Outlook

IONPATH EXPANDS PARTNERSHIPS FOR RAPIDLY DELIVER NOVEL INSIGHTS UTILIZING COMPANY'S HIGH-DEFINITION SPATIAL PROTEOMICS PLATFORM

IONpath, Inc. | August 27, 2021

Ionpath, Inc., the leader in high-definition spatial proteomics, today announced a new program for biopharmaceutical research organizations interested in piloting spatial phenotyping analyses of tissue samples leveraging the company's Multiplexed Ion Beam Imaging (MIBI™) technology. Through this new program, customers can benefit from in-depth immune profiling and spatial analysis performed with the company's 30-marker Checkpoint Panel on its MIBIscope™ System. ...

Read More
news image

OBSIDIAN THERAPEUTICS ANNOUNCES BRISTOL MYERS SQUIBB OPT-IN OF CYTODRIVE™ CELL THERAPY CANDIDATE

Obsidian Therapeutics | September 16, 2020

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first opt-in decision by Bristol Myers Squibb since the companies announced their collaboration to develop nov...

Read More
news image

Cell and Gene Therapy

EXACT SCIENCES ACQUIRES PREVENTIONGENETICS TO ACCELERATE AVAILABILITY OF HEREDITARY CANCER TESTING FOR MORE PATIENTS

Exact Sciences Corporation | January 10, 2022

Exact Sciences Corp. announced it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT). PreventionGenetics provides the clinical lab, expertise, and foundational technology necessary to accelerate the availability of HCT and help more patients know their germline risk of cancer and other diseases. "PreventionGenetics is a natura...

Read More
news image

Cell and Gene Therapy

CURI BIO CLOSES $10M SERIES A IN OVERSUBSCRIBED ROUND

Curi Bio Inc. | December 30, 2021

Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced the second closing of a $10 million oversubscribed Series A financing. New investors include UTC Investment and DS Asset Management, joining current Curi Bio investor and Series A lead Dynamk Capital. The investment will be used to scale Curi’s existing business and accelerate the development of its innovative engineered tissue analysis platforms, including its Mantarray™ platform.
Read More